Ariana's explainable AI applied to mechanistic modelling of radiation-induced oxidative stress, bridging pre-clinical evidence to clinical outcomes. Ariana Pharma® and USIL Therapeutics, a Luxembourg-based biopharmaceutical company developing innovative cytoprotective therapies, today announced a collaboration to develop a mechanistic AI model supporting the clinical evaluation of UT-241 in acute radiation syndrome (ARS). The collaboration addresses a critical unmet medical n

Ariana Pharma announces the appointment of Thomas Turcat as Chief Executive Officer. The transition marks a new chapter for Ariana Pharma as it expands the reach of its explainable AI technology with in-house drug development expertise - transforming small, heterogeneous clinical cohorts into regulatory-ready results that are logical and rule-association-based, while leveraging Thomas's broad commercial expertise. The output is transparent and explainable, giving research tea

Shteto, A., Boulahfa, J., Etcheto, A. et al. Genomic biomarkers of liver toxicity risk from UK Biobank data. Pharmacogenomics J 25, 30 (2025). Toxic liver disease represents one of the most serious safety challenges in drug development and clinical practice. In this study, Ariana Pharmaceuticals harnessed the power of explainable AI (eXp AI) through its proprietary KEM® (Knowledge Extraction & Management) platform to uncover genomic biomarkers associated with increased mortal